{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Birolini G"],"funding":["Telethon"],"pagination":["106823"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10463277"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["194"],"pubmed_abstract":["Evidence that Huntington's disease (HD) is characterized by impaired cholesterol biosynthesis in the brain has led to strategies to increase its level in the brain of the rapidly progressing R6/2 mouse model, with a positive therapeutic outcome. Here we tested the long-term efficacy of chronic administration of cholesterol to the brain of the slowly progressing zQ175DN knock-in HD mice in preventing (\"early treatment\") or reversing (\"late treatment\") HD symptoms. To do this we used the most advanced formulation of cholesterol loaded brain-permeable nanoparticles (NPs), termed hybrid-g7-NPs-chol, which were injected intraperitoneally. We show that one cycle of treatment with hybrid-g7-NPs-chol, administered in the presymptomatic (\"early treatment\") or symptomatic (\"late treatment\") stages i"],"journal":["Pharmacological research"],"pubmed_title":["Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease."],"pmcid":["PMC10463277"],"funding_grant_id":["GGP17102"],"pubmed_authors":["Favagrossa M","Ruozi B","Trucco A","Cappelleri A","Minoli L","Ottonelli I","Talpo F","Biella G","Passoni A","Nucera MR","Bagnati R","Caraffi R","Paltrinieri S","Taroni F","Scanziani E","Canevari C","Birolini G","Leoni V","Caccia C","Vandelli MA","Duskey JT","Valenza M","Tosi G","Salmona M","Colombo L","Bombaci M","Cattaneo E"],"additional_accession":[]},"is_claimable":false,"name":"Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease.","description":"Evidence that Huntington's disease (HD) is characterized by impaired cholesterol biosynthesis in the brain has led to strategies to increase its level in the brain of the rapidly progressing R6/2 mouse model, with a positive therapeutic outcome. Here we tested the long-term efficacy of chronic administration of cholesterol to the brain of the slowly progressing zQ175DN knock-in HD mice in preventing (\"early treatment\") or reversing (\"late treatment\") HD symptoms. To do this we used the most advanced formulation of cholesterol loaded brain-permeable nanoparticles (NPs), termed hybrid-g7-NPs-chol, which were injected intraperitoneally. We show that one cycle of treatment with hybrid-g7-NPs-chol, administered in the presymptomatic (\"early treatment\") or symptomatic (\"late treatment\") stages i","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-06-05T06:59:26.708Z","creation":"2025-04-04T19:24:08.638Z"},"accession":"S-EPMC10463277","cross_references":{"pubmed":["37336430"],"doi":["10.1016/j.phrs.2023.106823"]}}